Autologous CD133 + Cells and Laser Revascularization in patients with severe Ischemic Cardiomyopathy.
Ahmed Abdel-LatifTaha AhmedSteve W LeungTalal AlnabelsiWadea TarhuniMichael E SekelaPublished in: Stem cell reviews and reports (2022)
Our phase 1 clinical study examining the combination therapy of targeted transmyocardial laser revascularization therapy and autologous CD133 + endothelial progenitor cells in patients with chronic ICM and no revascularization options demonstrates the feasibility and short-term safety of this combined approach and warrants future larger phase 2 randomized clinical studies.
Keyphrases
- combination therapy
- percutaneous coronary intervention
- coronary artery bypass grafting
- double blind
- induced apoptosis
- cell therapy
- bone marrow
- heart failure
- cell cycle arrest
- platelet rich plasma
- nk cells
- open label
- high speed
- coronary artery disease
- acute coronary syndrome
- placebo controlled
- early onset
- stem cells
- phase iii
- endoplasmic reticulum stress
- signaling pathway
- ischemia reperfusion injury
- oxidative stress
- atrial fibrillation
- mesenchymal stem cells
- cell death
- drug induced
- subarachnoid hemorrhage